Changes in sleep disturbances and quality of life associated with Istradefylline in patients with Parkinson's disease: an exploratory polysomnographic study.
- 1Department of Clinical Pharmacology and Therapeutics, Ehime University Graduate School of Medicine, Toon, Ehime, Japan.
- 2Department of Neurology, Saiseikai Matsuyama Hospital, Matsuyama, Ehime, Japan.
Abstract
Background
Sleep disturbances are common non-motor symptoms in Parkinson's disease (PD) and substantially impair quality of life (QOL). Although istradefylline, an adenosine A2A receptor antagonist, is widely used to improve motor fluctuations, its effects on subjective sleep complaints and objective sleep architecture remain unclear.Methods
In this exploratory, single-center, open-label study, we evaluated changes in subjective sleep quality and polysomnographic findings following 12 weeks of istradefylline treatment in patients with PD. Nine patients underwent clinical assessments and overnight polysomnography at baseline and 12 weeks after initiating istradefylline (20 mg/day). Sleep quality, QOL, fatigue, and motor symptoms were assessed using validated clinical scales.Results
Following istradefylline initiation, improvements were observed in Parkinson's Disease Sleep Scale-2 (PDSS-2), Parkinson's Disease Questionnaire-39 summary index (PDQ-39 SI), Parkinson Fatigue Scale, and Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IV scores. Changes in PDSS-2 scores were significantly correlated with changes in PDQ-39 SI (ρ = 0.76, p = 0.017), although both measures were subjective and obtained at the same assessment. Regarding objective sleep measures, most polysomnographic parameters did not significantly change; rapid eye movement (REM) sleep percentage increased numerically, but the change was not statistically significant (p = 0.058).Conclusions
In this small uncontrolled study, initiation of istradefylline was associated with improvements in subjective sleep quality, fatigue, and QOL, whereas objective polysomnographic parameters showed limited changes. These findings are exploratory and hypothesis-generating and require confirmation in larger controlled studies.
Related
- Polysomnographic and nocturnal heart rate correlates of cognitive impairment in Parkinson’s disease: a cross-sectional study
- Vortioxetine-Associated Rapid Eye Movement (REM) Sleep Alterations: A Focused Narrative Review of Human Polysomnographic Evidence
- Multimodal analysis of sleep disturbances and heart disease in older adults: a machine learning and exploratory path analysis approach
- The whistle-smile reflex in Parkinson's disease: an exploratory case-control study
- Disease Duration Differentiates Freezing of Gait Response to Subthalamic and Nigral Stimulation for Parkinson's Disease in an Exploratory Multicenter Controlled Trial
BibTeX
@article{miyaue2026changes,
title = {{Changes in sleep disturbances and quality of life associated with Istradefylline in patients with Parkinson's disease: an exploratory polysomnographic study.}},
author = {Noriyuki Miyaue and Hayato Yabe},
journal = {Clinical parkinsonism \& related disorders},
year = {2026},
month = oct,
doi = {10.1016/j.prdoa.2026.100512},
url = {https://europepmc.org/article/MED/42921407},
note = {CC BY},
}
RIS
TY - JOUR
TI - Changes in sleep disturbances and quality of life associated with Istradefylline in patients with Parkinson's disease: an exploratory polysomnographic study.
AU - Noriyuki Miyaue
AU - Hayato Yabe
PY - 2026
DA - 2026/10/13
JO - Clinical parkinsonism & related disorders
DO - 10.1016/j.prdoa.2026.100512
UR - https://europepmc.org/article/MED/42921407
AB - Background Sleep disturbances are common non-motor symptoms in Parkinson's disease (PD) and substantially impair quality of life (QOL). Although istradefylline, an adenosine A2A receptor antagonist, is widely used to improve motor fluctuations, its effects on subjective sleep complaints and objective sleep architecture remain unclear.Methods In this exploratory, single-center, open-label study, we evaluated changes in subjective sleep quality and polysomnographic findings following 12 weeks of istradefylline treatment in patients with PD. Nine patients underwent clinical assessments and overnight polysomnography at baseline and 12 weeks after initiating istradefylline (20 mg/day). Sleep quality, QOL, fatigue, and motor symptoms were assessed using validated clinical scales.Results Following istradefylline initiation, improvements were observed in Parkinson's Disease Sleep Scale-2 (PDSS-2), Parkinson's Disease Questionnaire-39 summary index (PDQ-39 SI), Parkinson Fatigue Scale, and Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IV scores. Changes in PDSS-2 scores were significantly correlated with changes in PDQ-39 SI (ρ = 0.76, p = 0.017), although both measures were subjective and obtained at the same assessment. Regarding objective sleep measures, most polysomnographic parameters did not significantly change; rapid eye movement (REM) sleep percentage increased numerically, but the change was not statistically significant (p = 0.058).Conclusions In this small uncontrolled study, initiation of istradefylline was associated with improvements in subjective sleep quality, fatigue, and QOL, whereas objective polysomnographic parameters showed limited changes. These findings are exploratory and hypothesis-generating and require confirmation in larger controlled studies.
SN - 2590-1125
ER -